<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00395902</url>
  </required_header>
  <id_info>
    <org_study_id>20040261</org_study_id>
    <secondary_id>2004261</secondary_id>
    <nct_id>NCT00395902</nct_id>
  </id_info>
  <brief_title>Post Transplant Study</brief_title>
  <official_title>A Retrospective Evaluation of Sensipar Use in Renal Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      Retrospective chart review to gather information on Sensipar patterns of use and effects on
      biochemical parameters in renal transplant recipients
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <enrollment>50</enrollment>
  <condition>Kidney Tansplant</condition>
  <condition>Secondary Hyperparathyroidism</condition>
  <condition>Hyperparathyroidism</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sensipar after Post Transplant</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults &gt;= 18 years old

          -  Subjects who have received Sensipar for a duration of at least 3 months, beginning at
             least 3 months after a kidney transplant. Subjects must have begun Sensipar teatment
             no later than Februry 28, 2005 at treating physician's discretion.

        Exclusion Criteria:

          -  Subjects who received Sensipar before undergoing a kidney transplant

          -  Subjects receiving dialysis post-transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2006</study_first_submitted>
  <study_first_submitted_qc>November 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2006</study_first_posted>
  <last_update_submitted>December 20, 2007</last_update_submitted>
  <last_update_submitted_qc>December 20, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2007</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>Sensipar</keyword>
  <keyword>cinacalcet</keyword>
  <keyword>Mimpara</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cinacalcet Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

